Introduction
Gene therapy was initially developed as a strategy to treat monogenic diseases through the replacement of mutated gene with the wild-type counterpart. However, recently, much emphasis has been placed on the possibility to apply gene therapy in the treatment of diseases, many of which do not involve germline mutations. In corroborate with this development, there is an increasing interest in developing novel vectors that are safer and more efficient in gene delivery. Such new gene delivery methods would represent the pharmaceutical formulation of genes that will potentially compete well against conventional pharmaceutical, biological and surgical therapies, by offering improved effectiveness, safety and lower costs. Currently, human gene therapy products include naked DNA and viral as well as nonviral vectors containing nucleic acids. Viral vectors are usually immunogenic and possess potential oncogenicity and unknown long-term toxicity effects, whereas liposomes are generally referred to as comparatively 'safe'. 1, 2 Liposomes have been demonstrated to be able to deliver efficiently genes to pulmonary endothelium and hold promise for treating pulmonary metastasis and other diseases. [3] [4] [5] However, the application of liposome-DNA as vehicle for gene delivery is still hampered by the rapid induction of proinflammatory cytokines, such as TNF-a, IL-6, IL-12 and IFN-g, 6 ,7 that result mainly from the stimulation of immune cells by the unmethylated CpG motifs within the plasmid DNA. [8] [9] [10] The ability of naked plasmid DNA to mediate gene expression at substantive levels in mammalian cells was first demonstrated in muscle cells following the intramuscular injection of naked DNA. 11 Subsequently, the expression of exogenous gene delivered following the direct interstitial injection of naked DNA into rat liver, melanomas, pig epidermis, rabbit thyroid and lungs was also reported. [12] [13] [14] [15] Naked DNA has also been commonly employed for nucleic acid vaccination to induce cellular and humoral immune responses against pathogenic viruses, parasites, bacteria and tumors. 11, [16] [17] [18] [19] [20] [21] [22] The primary advantages of using DNA as immunogens directly include the ease to determine its purity, its stability, its ease to produce and its apparent ability to generate preferentially CD8 + T cells and Th1-based long-term antitumor immunity. 23 The intratumoral injection of naked DNA to elicit potent clinical therapeutic effects has also been documented. [24] [25] [26] [27] The in vivo delivery of naked DNA, nevertheless, suffers from the major drawback that it is easily degraded by endonucleases. Recently, Wolff and Liu reported an efficient pharmacodynamics-based plasmid DNA gene delivery method based on the change of the hydrodynamics of blood circulation in the recipient animals following the injection of a large volume of DNA solution within a short time. 12, 16 It has been demonstrated that the delivery of naked DNA for example, through intraportal injection or intrahepatic vein injection, could result in high level of gene expression. 12, 25, 26 However, high toxicity is observed with these methods of gene delivery, and their applications are therefore limited solely to experimental animal models but would not be feasible for clinical application.
To increase the therapeutic potentials of gene therapy and to reduce its toxicity, immense efforts have also been made to develop gene delivery vehicles that encompass cell-specific targeting elements. Limited success has been achieved either by directing the entry of the vectors to specific cell types, or by building gene expression cassettes that allow cell type-specific gene expression. In general, restriction of gene expression to specific cell types by employing tissue-specific transcription regulatory elements works satisfactorily. However, targeted gene delivery in vivo provides a greater challenge. There is a need for the greater understanding of the in vivo trafficking of DNA as well as its pharmacokinetics following systemic delivery to achieve optimal and targeted gene delivery. Nevertheless, the ability to target specific organs via systemic gene delivery of naked DNA offers a simple solution for targeted therapeutic gene delivery and circumvents many practical issues. We have, in the present manuscript, studied the feasibility of achieving kidney-specific gene expression via systemic delivery of naked DNA.
The successful delivery of biologically active molecules to the mammalian kidneys will undoubtedly have great therapeutic applications in treating renal and cardiovascular diseases. [28] [29] [30] [31] There is, however, currently no feasible gene delivery method that could allow the expression of exogenous DNA, to a satisfactory level, specifically in renal structures such as the tubules. The difficulties might be due to the special physiological features of the renal structures and the lack of specific targeting elements available for the mammalian kidney. Another contributing factor resulting in the poor delivery of DNA to the kidney could be related to its physiology where there is a constant flushing of fluid that may also lead to the loss of DNA following transfection. Given the fact that many renal diseases, such as renal cell carcinoma, are commonly originated from tubular epithelial cells, it would be paramount beneficial clinically if gene delivery could be targeted to the mammalian kidney and renal tubules. To enhance the potential of employing naked DNA for the gene therapy of renal carcinoma, we have studied the effects of the quantity and the volume of DNA employed for systemic injection on its stability in vivo and its subsequent level of expression in the kidneys of experimental mouse tumor model. In this study, we have demonstrated that it is possible to direct specific gene expression to the mammalian kidneys with established carcinoma following systemic delivery of naked DNA.
Results
Kidney-specific gene expression could be achieved by injection via the inferior vena cava of mice Previous reports have shown that intravenous injection of naked plasmid DNA did not result in gene expression in vivo. This is probably due to the presence of large amount of endonuclease in the circulation and as a result, the plasmid DNA is rapidly degraded following delivery into the blood circulation and no gene expression could be detected. In the present study, we have modified the route of delivery of naked plasmid DNA in vivo and to achieve gene expression in the mouse kidney following inferior vena cava (IVC) injection. Each mouse was injected with 0.2 ml of Ringer's buffer containing 100 mg of luciferase plasmid DNA via the IVC. Various organs were harvested from the injected mice 24 h after DNA infusion for luciferase and protein assay. Figure 1 showed that the level of gene expression in the kidney was 10-to 1000-fold higher than that of the other organs studied. Moreover, no animals died from the procedure and histological examination of the main organs revealed no evidence of tissue damage following gene delivery. In comparison, similar injection via the tail vein resulted in no detectable gene expression in all the organs tested ( Figure 1) , while large volume (1.5 ml) injection resulted in high level of gene expression only in the liver (Figure 1 ).
Kidney-specific gene expression via the IVC is independent of the volume of injection
To study if the volume of injection played a role in the specificity of targeting, each mouse was injected either with 0.2 or 0.5 ml of the DNA Ringer's buffer containing 100 mg of luciferase plasmid. Figure 2 demonstrates that both 0.2 and 0.5 ml injection volumes gave the same level of gene expression. Most importantly, the highest level of gene expression for the reporter gene was consistently associated with the kidney. Given that the 0.2 ml injection volume is easier to manipulate in the mice, we routinely employed 0.2 ml as the volume of injection for our subsequent experiments.
Stability of gene expression
Time-dependent specific gene expression in the kidney was also studied using plasmid DNA containing either the luciferase or b-galactosidase as reporter gene. Each mouse was injected with 100 mg of either luciferase or b-galactosidase plasmid DNA and killed at different time Relationship between the level of gene expression and the amount of DNA administered
To assess the effect of the amount of DNA on the efficiency and specificity of gene delivery and expression, a DNA dose-response curve was established.
A 10-150 mg portion of luciferase plasmid DNA in 0.2 ml Ringer's buffer was injected directly via the IVC into recipient mice. The levels of luciferase gene expression in various internal organs, including the liver, lung, spleen and kidney, were determined 24 h later.
Data in Figure 4 demonstrate that luciferase gene expression could be specifically detected in the kidney when the amount of DNA employed for injection was as low as 10 mg. The level of luciferase gene expression in the kidney increased steadily with the increase in the amount of DNA employed for IVC injection ( Figure 4 ). It was estimated that the level of luciferase gene expression in the kidney increased by approximately 100-fold when the DNA dose employed for injection increased from 10 to 100 mg ( Figure 4 ). Increasing the amount of injected DNA to 150 mg did not further significantly increase the amount of transgene produced (P40.05). The luciferase gene expression was saturated when 100 mg DNA was injected. However, the increase in the amount of DNA employed for IVC injection did not result in a similar increase in the luciferase gene expression in the other organs studied ( Figure 4 ).
Gene expression of the exogenous gene was mainly confined to the cortex and outer medullary region of the kidney
In addition to use of the luciferase gene as an assay system for gene expression, the LacZ gene and X-gal staining have also been employed to determine the localization of the transgene product. Each mouse was administered 100 mg of b-galactosidase (pLacZ) plasmid DNA in 0.2 ml Ringer's buffer via the IVC injection. The animals were killed 24 h following injection, perfused and the level of LacZ was determined using X-gal staining. As shown in Figure 5a (i), LacZ was mainly detected in the cortex (C) and outer medullary (OM) region of the kidney. In contrast, LacZ staining could not be detected in the kidney sections of control mice receiving the same amount of luciferase plasmid DNA iii) and (iv)). These data were further confirmed by confocal microscopy studies (Figure 5b ). At 10 min following the IVC injection, the DNA initially localized in the basement membrane of the proximal tubules (PT) (Figure 5b(i) ). After 30 min, the DNA subsequently migrated to the cytoplasm and nuclei of the proximal tubules (PT), but not to the distal tubules (DT) (Figure 5b (ii)), with the cytoplasm exhibiting the most intense staining (Figure 5b (ii)). When 10 random areas in the kidney tissue sections were chosen following X-gal staining to calculate the average number of positively stained tubules, it was concluded that strong LacZ gene expression could be detected on d1 following the IVC injection of bgalactosidase plasmid DNA (Table 1) . Approximately 40-70% of the tubules in the cortex were intensively stained with X-gal. X-gal-positive kidney tubular cells could still be detectable up to 35 days following IVC DNA injection (Table 1 ) and these positively stained cells were mainly localized in the corticomedullary junction.
To understand whether the plasmid DNA delivery via IVC injection elicited an immune response, we have studied the kidney sections following the IVC delivery method by immunohistochemical staining with antimouse CD11b, CD8 and CD4 antibodies. At various time points, namely, d1, d7 and d35 following the IVC delivery of DNA, we did not observe the specific accumulation of immune cells with the markers studied in the immunized mice in comparison to normal control mice.
Stability of DNA in the kidney following IVC injection
The degradation of exogenous DNA by serum and cellular nucleases is one of the main factors for the failure We have therefore compared the amount of the exogenous luciferase plasmid DNA that could be extracted from the kidney at various time points following gene delivery via IVC injection. Luciferase plasmid DNA (100 mg) was delivered in vivo via IVC injection and the recipient mice were killed at various times after injection. Following perfusion, the liver and kidney from each of the recipient mouse were collected and snap-frozen in liquid nitrogen. Plasmid DNA was then extracted from these organs and employed for Southern blot analysis and hybridization. The luciferase plasmid DNA was employed as the DNA hybridization probe. Figure 6 summarizes the results of a representative Southern blot hybridization. The amount and form of the plasmid DNA extractable from the kidneys of recipient mice following gene delivery via IVC as a function of time was analyzed ( Figure 6 ). It was observed that degradation of the exogenous plasmid DNA delivered via IVC injection took place relatively slowly as indicated by the presence of high-molecular-weight plasmid DNA smears in the kidney DNA samples collected 10 min following IVC injection ( Figure 6 , lanes 1-3). High-molecular-weight plasmid DNA smears could also be detected in the kidney 30 min following IVC injection ( Figure 6 , lanes 4-6). Although the exogenous luciferase plasmid DNA could still be detected in the kidney approximately 60 min following gene delivery via IVC, the DNA smears detected were of much lower molecular weight ( Figure 6 , lanes 7-9). In comparison, total genomic DNA similarly extracted from the liver of mice 10 min following the IVC injection did not demonstrate the presence of high-molecular-weight plasmid DNA following Southern blot hybridization with the luciferase DNA probe (data not shown).
The systemic DNA delivery to mammalian kidneys via IVC injection is applicable to experimental human kidney carcinoma established in SCID mice
In order to demonstrate that the IVC delivery system could also target gene delivery to tumor established in the kidneys, the human Caki-2 kidney carcinoma cells were inoculated under the kidney capsule. The formation of the tumor became noticeable on week 3 after inoculation of cancer cells. On d22, pLacZ plasmid DNA (100 mg/0.2 ml) was injected via IVC to tumor-bearing mice. The kidneys were harvested on days 1, 7 and 30 following IVC injection. The kidneys were cryosectioned and processed for X-gal staining. As shown in Figure  7A (a), transgene expression was mainly confined to the cortex (C) and outer medullary (OM) region of the kidney in SCID mice. This is comparable to the results obtained for normal Balb/c mice ( Figure 5(i) ). In Figure  5 , we have demonstrated that gene expression was mostly confined to the epithelial cells of the proximal convoluted tubule following IVC delivery and that more than 70% of these cells were transduced. With the Caki tumor cell model, the epithelial cells of the proximal convoluted tubule of the tumor-bearing mice were also transduced to similar degree as in normal animals. In addition, we also noticed that the DNA was also taken up by the Caki tumor cells and similarly over 70% of the tumor cells were transduced. The pLacZ expression lasted until d35, the last time point examined in our experiment ( Figure 7A(b) ). The duration of gene expression that was evaluated by measuring the average % of X-gal-positive tubules within the cortex and medullary regions was more than 40% at d35 (Table 1) . For the kidney with established tumor, the presence of the X-gal-positively stained blue cells was observed as early as d1 after injection ( Figure  7B(a-c) ). It was estimated that over 70% of the tumor cells were stained blue and these cells could be detected up to d35. Thus, IVC injection of naked DNA promoted the efficient and long-term gene expression specific to the kidney, including established carcinoma in the kidneys.
Discussion
Kidney-targeted gene therapy is a potential treatment modality for patients with either genetic or acquired Figure 6 Pharmacokinetics analysis of plasmid DNA in the kidney. Mice were injected with 100 mg of luciferase plasmid DNA and the kidneys were harvested at different time points after IVC injection as indicated. DNA were extracted and purified with phenol-chloroform. A 20 mg portion of total genomic DNA was digested to completion with BamHI and subjected to Southern blot and hybridization analyses. Plasmid DNA containing the luciferase gene was used as the positive control. Kidney-specific gene delivery X Wu et al renal diseases that lead to kidney destruction. The kidney is the main organ being affected in a number of inherited genetic diseases, including polycystic renal disease, Alport's syndrome, Fabry's disease, DenysDrash syndrome, nephronophtisis, nail-patella syndrome and nephrotic syndrome. 32 Alport's syndrome is an example of a hereditary renal disease that could be a suitable candidate for gene therapy. This disease, with a gene frequency of 1:5000, 33 is mainly X-chromosomelinked and caused by mutations in the type IV collagen a5 chain (COL4A5). [34] [35] [36] The symptoms of Alport's syndrome are mild to moderate hematuria and proteinuria, and the disease usually progresses to end-stage renal failure in males, leading to a need for continuous dialysis or renal transplantation. By delivering a normal copy of the type IV collagen a5 chain gene into cells of patients with X-linked Alport's syndrome, the defect could theoretically be corrected and the renal failure prevented. The autosomal dominant polycystic renal disease, loss of renal function due to multiple developing cysts, is another candidate for gene therapy. Furthermore, in renal transplantation, gene transfer can be used There are at least four potential routes for introducing genes into the kidneys. 30 Exogenous DNA could either be delivered via the renal artery, renal subcapsular site, retrograde from the ureter, or parenchymal injection. Both viral and nonviral gene delivery vectors have been employed to deliver genes to the kidney. Bosch et al 40 reported the successful transfer of the LacZ gene into the proximal tubules of rats after injuring the kidney transiently with a nephrotoxic dose of folic acid treatment with a retroviral vector. The injury stimulates regeneration of tubular cells that are necessary for infection with the retrovirus; otherwise, the majority of the adult renal tubular cells would be in a quiescent state and would not be infected. Moullier et al 41 have also demonstrated transient gene expression in the renal tubular cells of rats via a replication-defective adenoviral vector. The vector was delivered both by renal artery perfusion and retrograde infusion via the ureter. It was demonstrated that delivery via renal artery perfusion resulted in gene expression predominantly in the renal cortex; in comparison, retrograde infusion via the ureter resulted in strong expression mainly in papillary tubular cells. [41] [42] [43] Recently, Gusella et al 44 studied the transduction of kidney in mice after delivery of lentiviral vectors by various routes of administration. After parenchymal or ureteral infusion, expression of the transgene was localized to the outer medulla and corticomedullary junction. In the case of parenchymal injection, expression of the reporter gene extended to the cortex. On delivery of the lentiviral vector through the renal artery or vein, expression of the reporter gene was markedly lower than was observed with parenchymal or ureteral infusion and was limited to the inner medullary collecting ducts. 44, 45 It is apparent that viral and nonviral gene delivery vectors demonstrated quite different gene expression patterns when employed for kidney-specific gene delivery. Retroviral vectors direct gene expression predominantly in the outer medulla, 40 while adenoviruses could direct gene expression in either the outer medulla or inner medulla through different injection routes. [41] [42] [43] Renal arterial perfusion generated highest gene expression mainly in the outer medulla, while the highest gene expression is usually found in the papilla through retrograde infusion via the ureter. [41] [42] [43] In contrast, nonviral vectors consistently produce high gene expression either in the cortex or in the outer medulla and almost no expression could be detected in the inner medulla. 46 Lai et al 46 demonstrated a prolonged systemic gene expression in the kidney after intravenous delivery of DNA-liposome complex in mice. Although the level of exogenous gene expression in the kidney is relatively low, it was mostly restricted to the endothelium. 46 Lai et al 46 reported kidney-targeted gene delivery in mice using DOTMA-DOPE via intrarenal-pelvic or intrarenal-arterial injections. Gene expression was, however, mostly confined to the outer medulla. 46 Although the mechanism of DNA uptake mediated by nonviral gene delivery systems is not well characterized, it is possible that differences in the microenvironment between the inner and outer medulla would affect the interactions between the internalization of the exogenous DNA and the target cells for viral and nonviral vectors. Such differences in interactions at the local microenvironment may promote or prevent DNA uptake by the different target cells and could result in differences in gene expression. The expression of the transgene following the IVC injectionbased DNA transfection could be observed in all the internal organs examined including lung, liver, spleen, heart, with the highest level of transgene expression detected in the kidney. These results could be best explained by the anatomical flow of the injected DNA solution. Under the situation that plasmid DNA is injected via the tail vein, the DNA molecules enter the blood stream directly and are carried to the heart through which they are distributed to other organs. Because of the large amount of nuclease presence in the blood, the DNA molecules are quickly degraded. In comparison, when plasmid DNA is introduced via the IVC, the DNA molecules are carried firstly to the kidney, the nearest organ, via the renal vein and hence, enrich delivery of DNA to the kidney. The presence of intact plasmid DNA could be detected in the kidney within 10 min of the present IVC injection-based DNA transfection ( Figure 6 ). Since the circulatory system and the locations of its major organs in mice are similar to that of humans, our study should provide a reasonably good prediction of transgene expression in humans. However, one would require further biodistribution analyses in humans if the IVC delivery method is to be applied in humans. Another observation was that the injected naked DNA resided in the cytoplasm than in the nucleus (Figure 5b(ii) ). This might be one of the reasons for the poor efficiency of the naked DNA delivery system as compared to viral vectors that allow the integration of the DNA into the genome for viral vectors. Our present observation therefore further supports this suggestion. Two independent reporter gene systems, namely the firefly luciferase and b-galactosidase genes, were employed to monitor the expression of the transgene. The peak of luciferase expression was determined to be at 24 h following the IVC injection-based DNA transfection and rapidly declined thereafter to undetectable levels at d7 (Figure 3 ). In comparison, the transgene product of the b-galactosidase reporter gene persisted for more than 35 days ( Figure 7A ). This apparent disparity is most likely due to the differences in the intracellular stability of firefly luciferase and b-galactosidase and was consistent with reported data that the half-life of firefly luciferase was less than 2 h in vivo and in vitro, 47, 48 while the stability of b-galactosidase could last for more than 8 weeks when studied in lung and several other mammalian cell lines. [49] [50] [51] Alternatively, it may be due to variability in luciferase activities compared with the much stable b-galactosidase activities during sample preparation. tubular cells (Figure 5b) . Little or no expression of the exogenous gene could be detected in the distal convoluted tubules ( Figure 5 ). In comparison to the current methods available for targeting gene expression to the kidney, the present method of employing the naked DNA gene delivery system gave a similar gene expression pattern to the liposomal-mediated gene delivery systems. High gene expression is found in the corticomedullary region and almost no expression in the inner medulla. However, the cell type transduced in these two systems is different. While systemic injection of liposome-DNA complexes mainly transfected endothelial cells, 38 gene expression mostly resided in the tubular epithelial cells following intravenous injection of naked DNA ( Figure 5 ).
In conclusion, we have demonstrated the direct in vivo introduction of naked DNA to effect specific gene expression in the renal tubular cells. In addition, an important feature of IVC delivery of naked DNA is that it could achieve a high level of gene expression in kidney tumors ( Figure 7B ) without employing additional vector or special devices. The observed organ toxicity attributable to hydrostatic pressure resulting from large volume injection was also diminished. All these features should enable our present method to be particularly appealing for applications in cancer gene therapy and provide an ideal clinical alternative to the current gene delivery systems with targeted specificity to the kidney.
Materials and methods

Materials
The pNGVL-luciferase plasmid (5.6 kb) was obtained from Professor Leaf Huang (University of Pittsburgh) of which the luciferase gene was cloned into the backbone of pNGVL3 (obtained from the National Gene Vector Laboratory, MI, USA). The pcDNA3.1/HisB/lacZ plasmid (pLacZ, 8.6 kb) was purchased from Invitrogen (Carlsbad, CA, USA). Both of these two reporter gene systems employ the human cytomegalovirus (CMV) immediate-early promoter (CMV). The substrate, luciferin, employed in the luciferase assay was from Sigma (St Louis, MO, USA). The rediprime II DNA labeling system and [a-32 P]dCTP were purchased from Amersham (Piscataway, NJ, USA). Ringer's buffer solution was from B Braun Melsungen AG (Melsungen, Germany). SCID mice (6-8 weeks old) were purchased from the Charles River Laboratories (Wilmington, MA, USA). BALB/c mice (6-8 weeks old) were purchased from the animal center of the National University of Singapore. All the mice were used in accordance with our institutional guidelines on handling experimental animals.
The human kidney carcinoma cells, Caki-2, was purchased from American Type Culture Collection (Manassas, VA, USA) and cultured in McCoy's 5a medium containing 10% FBS.
IVC injection
Mice were anesthetized with the i.p. injection of ketamine (0.05 mg/g body weight). The IVC was exposed by midline incision and the DNA solution was directly administered to the IVC using a 30G needle (Terumo, Tokyo, Japan) within a few seconds. Hemostasis was achieved by local pressure over the injection site.
Analysis of luciferase gene expression
Animals were killed at the various time points as described in Results and the corresponding organs were harvested for assaying of the luciferase gene expression. The tissues harvested were homogenized in 0.7 ml of the lysis buffer (0.25 M sucrose, 2 mM EDTA, 0.1 mM PMSF, 10 mM Tris, pH 7.2). After three cycles of freezing and thawing, the homogenates were centrifuged at 14 000 g for 10 min at 41C. The expression level of the transgene was evaluated by measuring the relative light units in the various organs. A 10 ml portion of the supernatant was employed for the luciferase assay and 1 ml for protein assay.
Histochemical analysis of b-galactosidase gene expression in Caki-2-induced carcinoma in SCID mice One kidney of the SCID mouse was inoculated with 2 Â 10 6 Caki-2 cells in 50 ml Hank's buffer (Invitrogen's Gibco, CA, USA) under the kidney capsule. At 3 weeks after inoculation of tumor cells, mice injected with Caki-2 cells were examined and the presence of tumor in the outer cortex region was observed. A 100 mg portion of pLacZ plasmid DNA was injected into the IVC of SCID mice. At various time points following injection, the animals were perfused with 10 ml of PBS and 10 ml of 4% paraformaldehyde. Both kidneys were harvested and kept in 4% paraformaldehyde solution overnight and kept in 30% sucrose solution at 41C. The tissue was snapfrozen in liquid nitrogen and cryosectioned. Sections (20 mm) were cut and the sections mounted on slides and stained with a PBS solution containing 1 mg/ml X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside), 4 mM potassium ferricyanide, 4 mM potassium ferrocyanide and 2 mM MgCl 2 at 371C overnight. After washing, the sections were counterstained with eosin. The BALB/c mice the received 100 mg of pLacZ plasmid DNA were similarly processed. Mice that received injection of the pNGVL-Luc plasmids were employed as negative control.
For PAS staining, sections 5 mm in thickness were cut and these sections were mounted, stained with X-gal, followed by PAS and counterstained with eosin.
Confocal microscopy
For confocal microscopy studies, the luciferase plasmid DNA was labeled with the IT s TM-rhodamine DNA labeling kit from Mirus according to the procedure supplied by the manufacturer (Mirus, Madison, WI, USA). Kidney sections were prepared either 5 or 30 min after DNA infusion. The sections were washed 2 Â with PBS (5 min each) and nonspecific binding was prevented by employing 1% BSA in PBS as blocking solution. Following further washing with PBS, the sections were stained with 1 mg/ml FITC-phalloidin in PBS for 20 min at room temperature to allow the fluorescent labeling of F-actin. The slides were again washed 2 Â with PBS (5 min each) and dsDNAs were stained with a 1 mg/ml Hoechst 33342 solution, a cell-permeant, minor groovebinding nucleic acid stain, for 3 min. Hoechst 33342 fluoresces bright blue upon binding to DNA. After rinsing with PBS, the slides were mounted with the 
Southern blot analysis
Mice were injected with 100 mg of CMV-luc plasmid DNA into IVC and were perfused with PBS at the indicated time points, 10, 30 and 60 min postinjection. The target organs including liver and kidney were harvested and snap-frozen in liquid nitrogen. Total DNA was extracted from the homogenized tissues using a published procedure. 53 A 20 mg portion of total DNA from each sample was digested overnight at 371C using 60 U of BamHI and then separated on 0.8% agarose gel. DNA bands were then transferred to a Hybond Plus membrane for 5 h. After prehybridization in prehybridization buffer, the membrane was incubated at 421C for 16-20 h with 32 P-labeled luciferase plasmid. The hybridized bands were visualized by autoradiography.
